Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | CCKBR | P32239 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NMBR | P28336 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236150 | 0.87 | CCKBR (0.48) | CTSLCTSSCTSKMAPTSMN1; SMN2 | |
| SCHEMBL8236147 | 0.86 | MAPT (0.46) | CTSLCTSSCTSKMAPTSMN1; SMN2 | |
| SCHEMBL8242418 | 0.80 | KIF11 (0.39) | MAPTGAA | |
| SCHEMBL13608838 | 0.77 | CTSL (0.54) | CTSLCTSSCTSKMAPTTACR1 | |
| SCHEMBL18163918 | 0.76 | NPSR1 (0.40) | MAPTGAA | |
| SCHEMBL8242447 | 0.74 | MDM4 (0.43) | TP53 | |
| SCHEMBL4068546 | 0.74 | CTSL (0.56) | CTSLCTSSCTSKMAPTTACR1 | |
| SCHEMBL13620425 | 0.72 | CTSL (0.56) | CTSLCTSSCTSKMAPTNMBR | |
| SCHEMBL5494175 | 0.72 | CCKBR (0.59) | CTSLCTSSCTSKCCKBR | |
| SCHEMBL14509560 | 0.71 | HDAC3 (0.52) | CTSLCTSSCTSKMAPTTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | CUBIST PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | CTSL 124/4885CTSS 346/4885CTSK 309/4885 |
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | VIP, DNPEP, PREP | CTSL 124/4885CTSS 346/4885CTSK 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.